tramiprosate has been researched along with Cognition Disorders in 3 studies
tramiprosate: GABA receptor agonist and a glycosaminoglycan mimetic; has nootropic acitivity; structure; a sulfonate analog of GABA
3-aminopropanesulfonic acid : An amino sulfonic acid that is the 3-amino derivative of propanesulfonic acid.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Furthermore, in rat preclinical studies, 3-SPA displayed 100% oral bioavailability and 25% brain penetration, indicating that the metabolite is well absorbed and crosses the blood-brain barrier." | 2.87 | Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. ( Abushakra, S; Hey, JA; Hort, J; Kocis, P; Power, A; Tolar, M; Vyhnálek, M; Yu, JY, 2018) |
| "Homotaurine is a natural compound of red algae, which has been demonstrated to have a neuroprotective effect and has been evaluated as a possible therapeutic agent for Alzheimer's disease." | 2.80 | Homotaurine in Parkinson's disease. ( De Nigris, F; Fasano, A; Ricciardi, L; Specchia, A, 2015) |
| " 3xTg-AD mice (10-month-old) were dosed intraperitoneally with 9R (daily 3, 10 or 30 mg/kg) for a month." | 1.56 | 9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model. ( Ju, Y; Tam, KY, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ju, Y | 1 |
| Tam, KY | 1 |
| Hey, JA | 1 |
| Kocis, P | 1 |
| Hort, J | 1 |
| Abushakra, S | 1 |
| Power, A | 1 |
| Vyhnálek, M | 1 |
| Yu, JY | 1 |
| Tolar, M | 1 |
| Ricciardi, L | 1 |
| De Nigris, F | 1 |
| Specchia, A | 1 |
| Fasano, A | 1 |
2 trials available for tramiprosate and Cognition Disorders
| Article | Year |
|---|---|
Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Chromatography, Liquid; Cognition Di | 2018 |
Homotaurine in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Disorders of Excessive Somnolence; Female; Humans; | 2015 |
1 other study available for tramiprosate and Cognition Disorders
| Article | Year |
|---|---|
9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain Chemistry; Cholinesterase Inhibito | 2020 |